Invention Grant
US07884194B2 Soluble HER2 and HER3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
有权
可溶性HER2和HER3剪接变体蛋白，剪接切换寡核苷酸及其在治疗疾病中的应用
- Patent Title: Soluble HER2 and HER3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
- Patent Title (中): 可溶性HER2和HER3剪接变体蛋白，剪接切换寡核苷酸及其在治疗疾病中的应用
-
Application No.: US12157094Application Date: 2008-06-06
-
Publication No.: US07884194B2Publication Date: 2011-02-08
- Inventor: Ryszard Kole , Peter Sazani , Jing Wan
- Applicant: Ryszard Kole , Peter Sazani , Jing Wan
- Applicant Address: US OR Corvallis
- Assignee: AVI BioPharma Inc.
- Current Assignee: AVI BioPharma Inc.
- Current Assignee Address: US OR Corvallis
- Agency: Seed IP Law Group PLLC
- Main IPC: C07K14/485
- IPC: C07K14/485 ; C12N15/11
Abstract:
Soluble epidermal growth factor receptors 2 and 3 (HER2 and HER3) splice variant proteins with HER2 and HER3 antagonist activity and anti-proliferative properties, as well as the corresponding nucleic acids, are provided for treatment of proliferative diseases, in particular cancer. Also provided are compositions and methods for inducing expression of these splice variants, including splice switching oligonucleotides that modulate splicing of pre-mRNA that codes for these receptors.
Public/Granted literature
Information query
